PROF Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Profound Medical Corp (PROF) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has positive catalysts such as upcoming clinical data presentations and improving financial metrics, the technical indicators and lack of strong trading signals suggest waiting for more clarity or a better entry point.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 26.492, and moving averages are converging, showing no clear trend. Key support is at 4.933, and resistance is at 6.408. The stock is trading below its pivot point of 5.67, suggesting weakness.
Upcoming presentation of clinical CAPTAIN data at the European Association of Urology, which is considered one of the most important studies in prostate cancer.
Improved financial performance in Q4 2025, with revenue up 43.13% YoY and net income loss narrowing by 65.25%.
Lack of recent news or significant trading trends from hedge funds and insiders.
Technical indicators suggest bearish momentum and no clear upward trend.
Stock trend analysis shows a potential for negative returns in the short term.
In Q4 2025, revenue increased by 43.13% YoY to $5,977,000, and net income improved by 65.25% YoY to -$8,175,000. Gross margin increased to 74.32%, up 4.78% YoY. However, EPS dropped to 0, down 100% YoY, indicating challenges in profitability.
Lake Street analysts maintain a Buy rating with a price target of $12, citing the importance of upcoming clinical data and the company's improved capital position. The price target was raised from $11 to $12 earlier this year.
